THOUSAND OAKS dpaAFX Amgen AMGN announced Thursday that the Phase 3 GAUSS2 or Goal Achievement After Utilizing an AntiPCSK9 Antibody in Statin Intolerant Subjects2 trial evaluating evolo...
↧